NCT02016261View on ClinicalTrials.gov

Study to Evaluate Cognitive Functioning in Remitted Depression During Treatment With Fluvoxamine

PHASE4CompletedINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions

Recurrent Depressive Disorder

Interventions

DRUG

Fluvoxamine

The subjects will be prescribed Fluvoxamine treatment for 24 weeks with dose 50-300 mg

Trial Locations (1)

107076

Moscow Research Institution of Psychiatry, Moscow

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Abbott

INDUSTRY

lead

Moscow Research Institute of Psychiatry

OTHER